On November 5, 2020 City of Hope reported that it will present data on new findings on bone marrow transplants, immunotherapies and other blood cancer treatments at ASH (Free ASH Whitepaper) 62nd Annual Meeting and Exposition on Dec. 5 to 8, a virtual event (Press release, City of Hope, NOV 5, 2020, View Source [SID1234570189]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
City of Hope is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. The comprehensive cancer center was a pioneer in bone marrow and stem cell transplants — and the transplantation program is now one of the largest and most successful programs of its kind in the U.S. For the 15th year in a row, the Center for International Blood & Marrow Transplant Research has ranked City of Hope as providing exceptional care and strong clinical outcomes for patients who received bone or stem cell transplants; it is the only cancer center to hold this distinction.
During the ASH (Free ASH Whitepaper) virtual conference, City of Hope researchers will make presentations on the following and other data:
Title: Efficacy of Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial
Publication Number: 298
Type: Oral
Session Name: 732. Clinical Allogeneic Transplantation Results III
Session Date and Time: Saturday, Dec. 5, 2020, 2 to 3:30 p.m. ET
Presentation Time: 2:30 p.m.
Presenter: Monzr M. Al Malki, M.D., City of Hope Director of Unrelated Donor BMT Program and Haploidentical Transplant Program, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
Title: Consolidation With Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients With High-Risk Hodgkin Lymphoma
Publication Number: 472
Type: Oral
Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Clinical Studies in Hodgkin Lymphoma
Session Date and Time: Sunday, Dec. 6, 2020, 2 to 3:30 p.m. ET
Presentation Time: 2:30 p.m.
Presenter: Alex Herrera, M.D., City of Hope Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
Title: Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination With Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated With Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients With Acute Myeloid Leukemia (AML)
Publication Number: 192
Type: Oral
Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
Session Date and Time: Saturday, Dec. 5, 2020, Noon to 1:30 p.m. ET
Presentation Time: 12:45 p.m.
Presenter: Anthony S. Stein, M.D., City of Hope Associate Director, Gehr Family Center for Leukemia Research; Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation
Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
Publication Number: 75
Type: Oral
Session Name: 732. Clinical Allogeneic Transplantation: Results I
Session Date and Time: Saturday, Dec. 5, 2020, 7:30 to 9 a.m. ET
Presentation Time: 7:30 a.m.
Study Co-chair: Ryotaro Nakamura, M.D., City of Hope Director, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation